Site icon pharmaceutical daily

Global Idiopathic Pulmonary Fibrosis (IPF) Markets, 2017-2030 – Insights on Esbriet, Ofev, Tipelukast, Pamrevlumab, KD025, PRM 151, GKT831, and Other IPF Therapies – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030” report has been added to ResearchAndMarkets.com’s offering.

The Global Idiopathic Pulmonary Fibrosis (IPF) market held a market value of USD 2.07 billion in 2021 and is forecasted to reach USD 4.29 billion by the year 2030. The market is anticipated to register a CAGR of 8.4% over the projected period.

The growing geriatric population, increase in smokers’ population, and favourable support through funding for the pulmonary fibrosis research is anticipated to boost the market growth. Despite the driving factors, high treatment cost are expected to hinder the market growth during the forecast period.

Growth Influencers

Growing Geriatric Population

Geriatric population is more likely to suffer from idiopathic pulmonary fibrosis (IPF), which is likely to boost the market growth. According to the WHO, the geriatric population is expected to nearly double from 12% to 22% between 2015 and 2050. Also, according to Medscape, as of July 2021, approximately two third of IPF patients are above the age of 60 years. It also stated that in the U.S., the incidence rate of IPF in people aged 18 to 34 years is around 0.4-1.2 cases per 100,000 people and in people aged 75 years or older is ranged between 27.1-76.4 cases per 100,000 people. Therefore, growing geriatric population is expected to fuel the market growth over the projected period.

Increase in Smokers’ Population

According to BioNews, Inc., as of October 2021, current smokers are at higher risk of IPF as compared to former smokers. The exact cause of IPF is unknown, however smoking cigarettes is most probably the most well-established risk factor for IPF. The source also stated that, at the end of 2016, in a study, 27.2% of IPF patients were current smokers, 23.2% were former smokers, and 49.6% were never-smokers. Therefore, the growing smokers’ population is expected to boost the market growth.

Segments Overview

The Global Idiopathic Pulmonary Fibrosis (IPF) market is segmented based on therapy:

The Esbriet (Pirfenidone) segment is expected to account for the highest share of 30% in the U.S. market in 2021. This is because it has received the label of “conditional recommendation for IPF treatment”. The tipelukast segment is anticipated to grow at a CAGR of 8.7% in the UK market, owing to the growing number of players involved in the development of tipelukast.

Regional Overview

Based on region, the Global Idiopathic Pulmonary Fibrosis (IPF) market is divided into the U.S., EU5, and Japan.

The U.S. is estimated to account for the largest market share of over 60% in 2021 owing to the growing research activities for IPF and presence of a significant infrastructure for the development of innovative therapies.

EU5 is further divided into the UK, France, Germany, Spain, and Italy. The UK is expected to hold an opportunity of USD 232.2 million during 2021 to 2030. This is owing to the increasing prevalence of idiopathic pulmonary fibrosis in the country.

The prevalent population of IPF is usually based on the severity, gender, and age. In Japan, the prevalent population was 18.849. Similarly, in the U.S., the prevalent population of IPF, based on severity was 74,230 in 2021 and 1,27,397 in 2030 based on radiological markers of disease severity and 43,973 in 2021, based on the composite measures of disease severity.

Competitive Landscape

Currently marketed products include Esbriet (Pirfenidone) by Genentech, Inc. and Ofev by Boehringer Ingelheim Pharma GmbH & Co. KG. In March 2020, Esbriet received U.S. FDA’s Breakthrough Therapy Designation for adults suffering from unclassifiable interstitial lung disease. Similarly, in March 2020, Ofev by Boehringer Ingelheim GmbH received U.S. FDA approval for use as a first treatment for people suffering from chronic fibrosing interstitial lung diseases (ILDs). Also, in October 2021, Ofev was recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of adult patients suffering from chronic fibrosis ILD with a progressive phenotype, PF-ILD.

The market report provides insights on the below pointers:

The report answers questions such as:

Companies Profiled

For more information about this report visit https://www.researchandmarkets.com/r/g4fcc4

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version